Genetic Determinants of Cholestasis

Clinics in Liver Disease

Volumn 17, Issue 2, 2013, Pages 147-159

  Hirschfield, Gideon M ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Biliary transporters; Cholestasis; Genetics

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMINOPHOSPHOLIPID FLIPPASE; AMOXICILLIN PLUS CLAVULANIC ACID; BILE ACID; BOSENTAN; CANALICULAR TRASPORTER; CLAUDIN 1; CYCLOSPORIN A; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DICLOFENAC; ENZYME; ERYTHROMYCIN; FLUCLOXACILLIN; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P40; MULTIDRUG RESISTANCE RELATED PROTEIN 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; NOTCH2 RECEPTOR; OCCLUDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; RIFAMPICIN; STAT4 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ALAGILLE SYNDROME; ANTIGEN PRESENTING CELL; ARTHROGRYPOSIS RENAL DYSFUNCTION CHOLESTASIS SYNDROME; AUTOSOMAL RECESSIVE DISORDER; CHOLESTASIS; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; INTRAHEPATIC CHOLESTASIS; INTRAHEPATIC CHOLESTASIS OF PREGNANCY; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MACROPHAGE; PHENOTYPE; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTATIC DISEASE; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTATIC DISEASE 1; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTATIC DISEASE 2; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; TOXIC HEPATITIS;

AFIBRINOGENEMIA; ALAGILLE SYNDROME; CHOLANGITIS, SCLEROSING; CHOLESTASIS; CHOLESTASIS, INTRAHEPATIC; CYSTIC FIBROSIS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER CIRRHOSIS, BILIARY; P-GLYCOPROTEINS; PREGNANCY COMPLICATIONS;

EID: 84875602933     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.12.002     Document Type: Review

References (59)

1. Hirschfield G.M., Heathcote E.J., Gershwin M.E. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010, 139(5):1481-1496.
2. Paumgartner G. Biliary physiology and disease: reflections of a physician-scientist. Hepatology 2010, 51(4):1095-1106.
3. Groen A., Romero M.R., Kunne C., et al. Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity. Gastroenterology 2011, 141(5):1927-1937.e1-e4.
4. Wagner M., Zollner G., Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 2009, 51(3):565-580.
5. Halilbasic E., Claudel T., Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013, 58:155-168.
6. Clayton R.J., Iber F.L., Ruebner B.H., et al. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 1969, 117(1):112-124.
7. Nicolaou M., Andress E.J., Zolnerciks J.K., et al. Canalicular ABC transporters and liver disease. J Pathol 2012, 226(2):300-315.
8. Kubitz R., Droge C., Stindt J., et al. The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol 2012, 36:536-553.
9. Gonzales E., Grosse B., Cassio D., et al. Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol 2012, 57(3):695-698.
10. Jansen P.L., Strautnieks S.S., Jacquemin E., et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999, 117(6):1370-1379.
11. Keitel V., Burdelski M., Warskulat U., et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005, 41(5):1160-1172.
12. Evason K., Bove K.E., Finegold M.J., et al. Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies. Am J Surg Pathol 2011, 35(5):687-696.
13. Pawlikowska L., Strautnieks S., Jankowska I., et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol 2010, 53(1):170-178.
14. Strautnieks S.S., Byrne J.A., Pawlikowska L., et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 2008, 134(4):1203-1214.
15. Knisely A.S., Strautnieks S.S., Meier Y., et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006, 44(2):478-486.
16. Davit-Spraul A., Fabre M., Branchereau S., et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 2010, 51(5):1645-1655.
17. Jara P., Hierro L., Martinez-Fernandez P., et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med 2009, 361(14):1359-1367.
18. Davit-Spraul A., Gonzales E., Baussan C., et al. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009, 4:1.
19. Ziol M., Barbu V., Rosmorduc O., et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008, 135(1):131-141.
20. Gotthardt D., Runz H., Keitel V., et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008, 48(4):1157-1166.
21. Pasmant E., Goussard P., Baranes L., et al. First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis. Eur J Hum Genet 2012, 20(3):277-282.
22. Geenes V., Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009, 15(17):2049-2066.
23. Bacq Y., Sentilhes L., Reyes H.B., et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012, 143:1492-1501.
24. Wasmuth H.E., Glantz A., Keppeler H., et al. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 2007, 56(2):265-270.
25. Bacq Y., Gendrot C., Perrotin F., et al. ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. J Med Genet 2009, 46(10):711-715.
26. Rosmorduc O., Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007, 2:29.
27. Jacquemin E., Cresteil D., Manouvrier S., et al. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999, 353(9148):210-211.
28. Mullenbach R., Bennett A., Tetlow N., et al. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 2005, 54(6):829-834.
29. Dixon P.H., van Mil S.W., Chambers J., et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009, 58(4):537-544.
30. Sookoian S., Castano G., Burgueno A., et al. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 2008, 48(1):125-132.
31. Van Mil S.W., Milona A., Dixon P.H., et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007, 133(2):507-516.
32. Kamath B.M., Loomes K.M., Piccoli D.A. Medical management of Alagille syndrome. J Pediatr Gastroenterol Nutr 2010, 50(6):580-586.
33. Penton A.L., Leonard L.D., Spinner N.B. Notch signaling in human development and disease. Semin Cell Dev Biol 2012, 23(4):450-457.
34. Herrmann U., Dockter G., Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol 2010, 24(5):585-592.
35. Bartlett J.R., Friedman K.J., Ling S.C., et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009, 302(10):1076-1083.
36. Pall H., Zielenski J., Jonas M.M., et al. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr 2007, 151(3):255-259.
37. Keitel V., Cupisti K., Ullmer C., et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009, 50(3):861-870.
38. Smith H., Galmes R., Gogolina E., et al. Associations among genotype, clinical phenotype, and intracellular localization of trafficking proteins in ARC syndrome. Hum Mutat 2012, 33:1656-1664.
39. Grosse B., Cassio D., Yousef N., et al. Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability. Hepatology 2012, 55(4):1249-1259.
40. Bull L.N., Roche E., Song E.J., et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000, 67(4):994-999.
41. Hirschfield G.M., Liu X., Xu C., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009, 360(24):2544-2555.
42. Walker E.J., Hirschfield G.M., Xu C., et al. CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population. Arthritis Rheum 2009, 60(4):931-937.
43. Hirschfield G.M., Liu X., Han Y., et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010, 42(8):655-657.
44. Liu X., Invernizzi P., Lu Y., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010, 42(8):658-660.
45. Mells G.F., Floyd J.A., Morley K.I., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011, 43(4):329-332.
46. Hirschfield G.M., Xie G., Lu E., et al. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun 2012, 13(4):328-335.
47. Juran B.D., Hirschfield G.M., Invernizzi P., et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet 2012, 21:5209-5221.
48. Poupon R., Ping C., Chretien Y., et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008, 49(6):1038-1045.
49. Melum E., Franke A., Schramm C., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011, 43(1):17-19.
50. Janse M., Lamberts L.E., Franke L., et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011, 53(6):1977-1985.
51. Folseraas T., Melum E., Rausch P., et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012, 57(2):366-375.
52. Naess S., Shiryaev A., Hov J.R., et al. Genetics in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol 2012, 36:325-333.
53. Lucena M.I., Molokhia M., Shen Y., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141(1):338-347.
54. Daly A.K., Donaldson P.T., Bhatnagar P., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41(7):816-819.
55. Lang C., Meier Y., Stieger B., et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007, 17(1):47-60.
56. Dawson S., Stahl S., Paul N., et al. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 2012, 40(1):130-138.
57. Padda M.S., Sanchez M., Akhtar A.J., et al. Drug-induced cholestasis. Hepatology 2011, 53(4):1377-1387.
58. Daly A.K., Aithal G.P., Leathart J.B., et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007, 132(1):272-281.
59. Andrews E., Armstrong M., Tugwood J., et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010, 51(5):1656-1664.